APVO - アプテボ・セラピュ―ティクス （Aptevo Therapeutics Inc.） アプテボ・セラピュ―ティクス

Aptevo Therapeutics press release (APVO): FY GAAP EPS of $1.57 beats by $0.64.Revenue of $3.11M (-74.7% Y/Y) in-line.Aptevo had cash and cash equivalents as of December 31, 2022…

Aptevo Therapeutics (APVO) has raised $9.6M in non-dilutive funding, extending its cash runway beyond 12 months with an additional $50K possible based on IXINITY sales in 1Q 23.The…

Acquired IXINITY® commercial payment and milestone economics from Aptevo Therapeutics Acquired IXINITY® commercial payment and milestone economics from Aptevo Therapeutics

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics. The rewards for bringing such products to market are significant. But biotech growth stocks also generally carry much higher risk than the average stock. Additionally, companies in the biotech industry face regulatory approval processes and intellectual property disputes that can result in significant near-term volatility. Nevertheless, the potential for substantial returns makes biotech stocks perpetually attractive. Identifying companies with the best chances of developing breakthrough drugs or therapies is paramount to success. Let’s take a look at seven companies that I think fit that profile. ITOS iTeos Therapeutics $17.30 VIR Vir Biotechnology $22.84 BEAM Beam Therapeutics $39.10 KNSA Kiniksa Pharmaceuticals $12.28 DVAX Dynavax Technologies $10.44 CMRX Chimerix $1.63 APVO Aptevo Therapeutics $2.15 iTeos Therapeutics (ITOS) Source: motorolka / Shutterstock.com Stocks like iTeos Therapeutics (NASDAQ: ITOS ) are the kind of equity biotech investors ought to be looking for.

Trial to Evaluate Safety, Tolerability and Clinical Activity in Solid Tumors Expressing 5T4 LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / February 13, 2023 / Alligator Bioscience AB ("Alligator") (Nasdaq Stockholm: ATORX) and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced the dosing of the first patient in the companies'' Phase 1 trial evaluating ALG.APV-527 for the treatment of solid tumors expressing the tumor-associated antigen 5T4. ALG.APV-527 is a bispecific antibody with a tumor-directed 4-1BB agonistic effect and the ability to specifically stimulate antitumor-specific T cells and NK cells involved in tumor control. "We are very pleased to announce the initiation of a clinical trial to evaluate ALG.APV-527 in patients with solid tumors with high prevalence of 5T4. For Aptevo, the initiation of a second clinical program means we are now developing therapeutics to treat both solid tumors and hematological malignancies - a strategic win for our company," said Marvin White, President, and CEO of Aptevo. "ALG.APV-527 is a compelling candidate, as preclinical studies showed it has the potential to activate key immune cell populations within the tumor microenvironment while demonstrating a favorable safety profile.

Aptevo Therapeutics press release (APVO): Q3 GAAP EPS of -$1.50 beats by $0.14.Aptevo had cash, cash equivalents and restricted cash of $22.6 million as of September 30, 2022

ALG.APV-527 Demonstrates Favorable Preclinical Efficacy and Safety Compared to a First Generation 4-1BB AntibodyALG.APV-527 Rapidly Progressing to Clinical Development for Evaluation in the Treatment of Solid Tumors after Receipt of IND Clearance …

Company to Present New Data from On-Going Phase 1b Trial Evaluating Lead Candidate APVO436 for the Treatment of Acute Myeloid Leukemia SEATTLE, WA / ACCESSWIRE / November 3, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced acceptance of a poster presentation at 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13 in New Orleans, Louisiana. Details of the presentation, which will be presented live, are as follows: Title: " Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 ADAPTIR™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome" Date/Time: Sunday, December 11, 2022, 6:00 PM-8:00 PM Presenter: Justin M. Watts, MD, Associate Professor of Medicine Section Chief, Leukemia, Pap Corps Endowed Professor in Leukemia, Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine About Aptevo Therapeutics Inc.

Alligator Bioscience and Aptevo Therapeutics (APVO) said the U.S

Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tumor antigens in multiple solid tumor typesLUND, SWEDEN and SEATTLE WA / ACCESSWIRE / September 19, 2022 / Alligator Bioscience AB ("Alligator") and Aptevo …

Aptevo Therapeutics (APVO) traded higher in the morning hours Thursday after the clinical-stage biotech announced new remission data on four additional patients enrolled in its Phase…

Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to DateCohort 3 Monotherapy Patient Achieved Bone Marrow Complete RemissionCompany Also Reports Myelodysplastic Syndrome Patient Enrolled in Dose …

Aptevo Therapeutics press release (NASDAQ:APVO): Q1 GAAP EPS of -$1.59 misses by $0.66.Revenue of $3.11M (+28.5% Y/Y) misses by $0.64M.

SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and …

Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant DiseaseSEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage …